ATE219838T1 - Verwendung von funktionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie - Google Patents

Verwendung von funktionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie

Info

Publication number
ATE219838T1
ATE219838T1 AT96107522T AT96107522T ATE219838T1 AT E219838 T1 ATE219838 T1 AT E219838T1 AT 96107522 T AT96107522 T AT 96107522T AT 96107522 T AT96107522 T AT 96107522T AT E219838 T1 ATE219838 T1 AT E219838T1
Authority
AT
Austria
Prior art keywords
functional derivatives
adhesion molecule
intercellular adhesion
molecule icam
antivirus
Prior art date
Application number
AT96107522T
Other languages
English (en)
Inventor
Timothy Alan Springer
Original Assignee
Blood Res Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blood Res Center filed Critical Blood Res Center
Application granted granted Critical
Publication of ATE219838T1 publication Critical patent/ATE219838T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96107522T 1989-03-16 1990-03-08 Verwendung von funktionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie ATE219838T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32407389A 1989-03-16 1989-03-16
US45429289A 1989-12-22 1989-12-22

Publications (1)

Publication Number Publication Date
ATE219838T1 true ATE219838T1 (de) 2002-07-15

Family

ID=26984265

Family Applications (2)

Application Number Title Priority Date Filing Date
AT90104450T ATE146968T1 (de) 1989-03-16 1990-03-08 Verwendung von funkionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie
AT96107522T ATE219838T1 (de) 1989-03-16 1990-03-08 Verwendung von funktionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT90104450T ATE146968T1 (de) 1989-03-16 1990-03-08 Verwendung von funkionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie

Country Status (12)

Country Link
EP (2) EP0391088B1 (de)
JP (1) JP3166854B2 (de)
KR (1) KR0178024B1 (de)
AT (2) ATE146968T1 (de)
AU (1) AU648016B2 (de)
CA (1) CA2012125C (de)
DE (2) DE69029528T2 (de)
DK (2) DK0745852T3 (de)
ES (2) ES2097748T3 (de)
GR (1) GR3022846T3 (de)
HU (1) HU220235B (de)
NZ (1) NZ232920A (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
DE68929096T2 (de) 1988-09-01 2000-05-11 Bayer Corp., Pittsburgh Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
DK0387668T3 (da) * 1989-03-09 1997-03-03 Blood Res Center Intercellulært adhæsionsmolekyle-2 og dets bindende ligander
WO1991018010A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
EP0468257B1 (de) * 1990-07-20 1999-09-01 Bayer Corporation Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
EP0510483A1 (de) * 1991-04-22 1992-10-28 Boehringer Ingelheim Pharmaceuticals Inc. Verfahren zum Nachweis von Viren
EP0650367A4 (de) * 1992-06-01 1998-04-15 New England Medical Center Inc Verhinderung interzellulärer wechselwirkungen mit chimären cd43-molekülen.
DE4335273A1 (de) * 1993-10-15 1995-04-20 Univ Ludwigs Albert Peptide zur Tumortherapie
EP0757697A4 (de) * 1994-04-12 2000-05-17 Boehringer Ingelheim Pharma Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges
EP0762886A4 (de) * 1994-04-19 1999-03-31 Univ Kansas Icam-1/lfa-1 kurzkettigen peptide und methoden zu deren verwendung
US6373598B1 (en) 1995-11-16 2002-04-16 Brother Kogyo Kabushiki Kaisha Facsimile machine for use in combination with PC
ATE258057T1 (de) * 1995-11-22 2004-02-15 Univ Montana State Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
DK0885010T3 (da) * 1996-03-06 2003-09-15 Boehringer Ingelheim Pharma Pulverformigt lægemiddel indeholdende intercellulært adhæsionsmolekyle
US6075004A (en) * 1996-04-26 2000-06-13 The University Of Kansas Peptide compositions which induce immune tolerance and methods of use
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
JP4880153B2 (ja) 1999-06-24 2012-02-22 ザ ジョンズ ホプキンス ユニヴァーシティ Ｈｉｖの経上皮伝染を予防する組成物および方法
GB0216729D0 (en) * 2002-07-18 2002-08-28 Glaxo Group Ltd Animal models

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080044T3 (es) * 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular y sus ligandos de fijacion.
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor
DE68929096T2 (de) * 1988-09-01 2000-05-11 Bayer Corp., Pittsburgh Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
WO1990003400A1 (en) * 1988-09-28 1990-04-05 Dana-Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
NO900155L (no) * 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.

Also Published As

Publication number Publication date
EP0745852B1 (de) 2002-06-26
EP0391088A3 (de) 1991-10-02
HU220235B (hu) 2001-11-28
ATE146968T1 (de) 1997-01-15
JP3166854B2 (ja) 2001-05-14
AU5129490A (en) 1990-09-20
KR0178024B1 (ko) 1999-03-20
DK0391088T3 (da) 1997-06-16
KR900013984A (ko) 1990-10-22
HK1003104A1 (en) 1998-10-09
JPH0372430A (ja) 1991-03-27
HUT56133A (en) 1991-07-29
ES2097748T3 (es) 1997-04-16
ES2177695T3 (es) 2002-12-16
DE69033983D1 (de) 2002-08-01
DE69029528T2 (de) 1997-06-26
NZ232920A (en) 1997-05-26
DK0745852T3 (da) 2002-10-14
CA2012125A1 (en) 1990-09-16
EP0391088A2 (de) 1990-10-10
HU901585D0 (en) 1990-06-28
EP0391088B1 (de) 1997-01-02
CA2012125C (en) 2003-07-29
EP0745852A1 (de) 1996-12-04
DE69033983T2 (de) 2003-03-20
GR3022846T3 (en) 1997-06-30
DE69029528D1 (de) 1997-02-13
AU648016B2 (en) 1994-04-14

Similar Documents

Publication Publication Date Title
ATE146968T1 (de) Verwendung von funkionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie
DE69008664D1 (de) Bestrahlung von bluterzeugnissen.
FI952302L (fi) Pyran-2-onit ja 5,6-dihydropyranonit, jotka ovat käyttökelpoisia HIV:n ja muiden retrovirusten hoidossa
FI890582A7 (fi) Biosidisten aineiden emulgoituvat konsentraatit, niistä valmistetut vesipitoiset mikroemulsiot ja näiden mikroemulsioiden käyttö puutavaran käsittelyyn
DE3781240D1 (de) Vorrichtung zur stimulation von gliedversteifungen.
DE3854700D1 (de) Verwendung von wässrigen kationischen Kunststoffdispersionen zum Imprägnieren und Grundieren von saugfähigen Substraten.
GR3006073T3 (de)
FI875544A7 (fi) 3'-deoksitymidin-2'-eenin (3'-deoksi-2',3'-didehydrotymidiini) käyttö retroviruksilla infektoituneiden potilaiden hoitoon.
DE3751576D1 (de) Virale Inaktivierung und Reinigung von aktiven Proteinen.
FI925261A7 (fi) Virushepatiitin diagnoosi ja hoito
FI874166A7 (fi) 2',3'-dideoksisytidin-2'-eenin käyttö retroviruksilla infektoituneiden potilaiden hoitoon.
DE3767550D1 (de) Oberflaechenbehandlung von titangegenstaenden.
DE68910320D1 (de) Behandlung von holz und auf holz basierenden stoffen.
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
DE3675654D1 (de) Nach amplitude ausgeglichenes und anpassbarer laser.
DE3767175D1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
FI863159A7 (fi) Sydänlääkkeinä käytettäviä heterosyklokarbonyyli- ja asetyylitiatsoloneja.
EP0757697A4 (de) Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges
ATE143058T1 (de) Typisierung humaner rhinoviren
DE3777022D1 (de) Verfahren und praeparat zur inaktivierung von viren.
DE3863093D1 (de) Sulfosuccinamidsaeuren von polyoxypropylendiaminen und ihre verwendung als emulgatoren.
DE3886765D1 (de) Derivate von synergimycinen a und b.
DE69002234D1 (de) Ultraschallbehandlung von teigerzeugnissen.
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DE69430188D1 (de) Behandlung von hiv-infektionen mittels huminsäure

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time